Results 111 to 120 of about 5,863 (219)

Deep phenotyping of the unselected COPSAC2010 birth cohort study [PDF]

, 2013
BACKGROUND: We hypothesize that perinatal exposures, in particular the human microbiome and maternal nutrition during pregnancy, interact with the genetic predisposition to cause an abnormal immune modulation in early life towards a trajectory to chronic
Bischoff, Anne Louise, Bisgaard, Hans Flinker, Bjarnadóttir, E., Bønnelykke, K., Carson, C. G., Chawes, Bo Lund Krogsgaard, Følsgaard, Nilofar Vahman, Kreiner‐Møller, E., Krogfelt, Karen Angeliki, Lauritzen, L., Mortensen, L. J., Nilsson, E., Olsen, S. F., Pedersen, L., Pedersen, Susanne Brix, Schjørring, S., Stokholm, J., Thysen, Anna Hammerich, Vissing, Nadja Hawwa   +18 more
core   +1 more source

Advances in immunomodulating therapy of HBV infection [PDF]

, 2000
Patients with chronic hepatitis B virus (HBV) infection have a higher risk of developing liver cirrhosis and hepatocellular carcinoma. Interferon-α, lamivudine and adefovir dipivoxil are the three approved treatment for chronic HBV infection and offers ...
Hui, CK, Lau, GKK
core  

Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older [PDF]

, 2014
BACKGROUND: The effectiveness of trivalent influenza vaccines may be reduced in older versus younger adults because of age-related immunosenescence. The use of an adjuvant in such a vaccine is one strategy that may combat immunosenescence, potentially by
A Kelso, AM Harandi, AR Falsey, B Weinberger, Béatrice Laupèze, Carine Claeys, Caroline Hervé, CG Della, Concepción Núñez López, Covadonga Caso, DM Murasko, DT O’Hagan, DW Scheifele, F Roman, F Roman, G Galli, GK Pedersen, HC Rümke, HT Maecker, I Leroux-Roels, I Mbawuike, Innocent Nnadi Mbawuike, JE McElhaney, JE McElhaney, JE McElhaney, JE McElhaney, JE McElhaney, JE McElhaney, José M Bayas, JP Hsu, JS Lefebvre, JY Song, K Goodwin, K Levie, KK McKinstry, Lidia Oostvogels, LT Reed, M Ferguson, MD Co, Mohamed El Idrissi, N Garçon, N Hehme, NW Hehme, O Boyman, P Moris, P Sfriso, Philippe Moris, Robert B Couch, S Heijmans, S Morel, S Sridhar, SE Bentebibel, SL Waldrop, T Vesikari, TM Wilkinson, TW Clark, WA Keitel, X Zhou, Y Deng, YD Mahnke   +59 more
core   +1 more source

MF59™-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations

Expert Review of Vaccines, 2007
Influenza is a highly contagious respiratory disease associated with substantial morbidity and mortality in vulnerable populations, especially the elderly. Influenza viruses are unique in that they undergo small mutations and antigenic variation in their hemagglutinin and neuraminidase genes. Owing to the senescence of the immune system, the ability to
Joan, Puig Barberà, David, González Vidal   +1 more
openaire   +2 more sources

The history of MF59 ^® adjuvant: a phoenix that arose from the ashes

Expert Review of Vaccines, 2013
The first clinical trial of an MF59(®)-adjuvanted influenza vaccine (Novartis) was conducted 20 years ago in 1992. The product that emerged (Fluad(®), Novartis) was licensed first in Italy in 1997 and is now licensed worldwide in 30 countries. US licensure is expected in the coming years. By contrast, many alternative adjuvanted vaccines have failed to
Derek T, O'Hagan, Gary S, Ott, Gary Van, Nest, Rino, Rappuoli, Giuseppe Del, Giudice   +4 more
openaire   +2 more sources

Application of a novel nanoemulsion adjuvant for rabies vaccine which stabilizes a Krebs cycle intermediate (SDH) in an animal model

Human Vaccines & Immunotherapeutics, 2019
Rabies is the most lethal zoonotic, vaccine-preventable viral disease in the world. Its treatment is complicated by insufficient vaccine supply and the requirement for four to five repeated injections, as commercially available inactivated rabies lack ...
Liu Ze, Li Zonglin, Wu Ya’Nan, Song Shaohui, Yang Huijuan, Cai Wei, Weidong Li, Guoyang Liao   +7 more
doaj   +1 more source

Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore), 2020
Yang J, Zhang J, Han T, Liu C, Li X, Yan L, Yang B, Yang X.   +7 more
europepmc   +1 more source

MF59 adjuvanted seasonal and pandemic influenza vaccines.

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2012
MF59-adjuvanted seasonal trivalent inactivated (ATIV) vaccine licensed since 1997 and MF59-adjuvanted pandemic H1N1 vaccines have been distributed to approximately 80M persons. Addition of the emulsion adjuvant to inactivated vaccine formulations provides for higher levels of antibody to the viral hemagglutinin (HA) in less responsive older adults ...
openaire   +1 more source

Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in seropositive solid organ transplant recipients: anti-AD2 levels correlate with protection from viraemia [PDF]

, 2018
The human cytomegalovirus (HCMV) virion envelope protein glycoprotein B (gB) is essential for viral entry and represents a major target for humoral responses following infection.
Baraniak, IA, Griffiths, P, Kropff, B, Mach, M, McLean, G, Milne, RSB, Pichon, S, Reeves, M, Smith, C   +8 more
core  

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity

Expert Review of Vaccines, 2010
Approximately 70 years passed between the licensing of alum salts as vaccine adjuvants and that of MF59™ MF59, an oil-in-water emulsion, is currently licensed for use in the elderly as an adjuvant in seasonal influenza vaccines. Its mechanism of action is not fully understood, but enhancement of the interaction between the antigen and the dendritic ...
openaire   +1 more source